Literature DB >> 9352259

Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1.

K Leriche-Guérin1, M A Trabaud, L Cotte, F Bissuel, E Deruelle, P Rougier, C Trépo.   

Abstract

To evaluate the correlation between zidovudine (ZDV) resistance mutations of human immunodeficiency virus type 1 (HIV-1), biological parameters, and clinical evolution, 111 HIV-1-infected patients treated with ZDV were studied. Specific mutations at codons 70, 215, and 41 in the HIV-1 reverse transcriptase coding region conferring resistance to ZDV were detected using a selective polymerase chain reaction. The appearance of ZDV resistance mutations was significantly correlated with baseline clinical stage, CD4+ cell count, and viral load, but not with duration of ZDV therapy or p24 antigen level. In univariate analysis, results showed a prognostic role of mutations at codons 215 and 41 for clinical progression to the acquired immune deficiency syndrome (AIDS) or death. In multivariate analysis after controlling for viral load, CD4+ cell count, and clinical stage, the presence of the mutation at codon 215 (but not at codon 41) remained an independent predictor of subsequent clinical evolution.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352259     DOI: 10.1007/bf01708556

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

Review 2.  Clinical significance of drug resistance in human immunodeficiency virus.

Authors:  D D Richman
Journal:  Clin Infect Dis       Date:  1995-10       Impact factor: 9.079

3.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

Authors:  B A Larder; P Kellam; S D Kemp
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

4.  Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.

Authors:  J S Montaner; J Singer; M T Schechter; J M Raboud; C Tsoukas; M O'Shaughnessy; J Ruedy; K Nagai; H Salomon; B Spira
Journal:  AIDS       Date:  1993-02       Impact factor: 4.177

5.  The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.

Authors:  T C Merigan; R L Hirsch; A C Fisher; L A Meyerson; G Goldstein; M A Winters
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

6.  Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy.

Authors:  S Land; C McGavin; R Lucas; C Birch
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

7.  HIV-1 sensitivity to zidovudine and clinical outcome in children.

Authors:  G Tudor-Williams; M H St Clair; R E McKinney; M Maha; E Walter; S Santacroce; M Mintz; K O'Donnell; T Rudoll; C L Vavro
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

8.  Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

Authors:  A J Japour; S Welles; R T D'Aquila; V A Johnson; D D Richman; R W Coombs; P S Reichelderfer; J O Kahn; C S Crumpacker; D R Kuritzkes
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

9.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

10.  Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness.

Authors:  J P Ioannidis; J C Cappelleri; J Lau; P R Skolnik; B Melville; T C Chalmers; H S Sacks
Journal:  Ann Intern Med       Date:  1995-06-01       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.